# US 6,727,247 B2 · Substituted benzothiazole amide derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,247 B2
- Document ID: US6727247B2
- Status: Granted
- Kind: B2
- Application number: 10/308,338
- Filed: 2002-12-03
- Published: 2003-08-07
- Granted: 2004-04-27
- Earliest claimed: 2001-12-10
- Assignees: Hoffman-La Roche Inc.
- Inventors: Alexander Flohr; Roland Jakob-Roetne; Roger David Norcross; Claus Riemer
- Web page: https://patentgrep.com/patent/US6727247B2

## CPC

- A61K 31/428: condensed with carbocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 11/16: Central respiratory analeptics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 277/82: Nitrogen atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 451/06: Oxygen atoms
- C07D 453/06: containing isoquinuclidine ring systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D 491/08: Bridged systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound of formula I and a method of treatment of diseases, related to modulation of the adenosine A2 receptor system comprising administering a compound of formula to a person in need of such treatment.

## Claims

### Claim 1

A compound of formula
wherein
R is lower alkoxy or halogen;
R11 and R2, together with the N atom to which they are attached, form a heterocyclic ring, said heterocyclic ring being unsubstituted or substituted by lower alkyl, selected from the group consisting of
2-oxa-5-aza-bicyclo[2.2.1]heptane,
3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane,
2-aza-bicyclo[2.2.2]octane,
1-oxo-2,8-diaza-spiro[4.5]decane,
3-aza-spiro[5.5]undecane,
8-aza-spiro[4.5]decane,
1-oxa-8-aza-spiro[4.5]decane,
1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane,
[1,4]oxazepane,
2-oxa-5-aza-bicyclo[2.2.2]octane,
8-oxa-3-aza-bicyclo[3.2.1]octane,
1,4-diaza-bicyclo[3.2.1]octane,
2-aza-bicyclo[2.2.1]heptane and
3-aza-bicyclo[3.2.1]octane, or
piperidin-1-yl, substituted by a substituent selected from the group
—(CH2)n—NR′S(O)2-lower alkyl, —C(O)NR′2 and —(CH2)n-phenyl, said phenyl ring being unsubstituted or substituted by lower alkyl, and R′ being i dependently selected from hydrogen and lower alkyl;
X is —O—; and
n is 0,1,2,3 or 4;
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 2 (depends on 1)

The compound of formula IA according to claim 1, selected from the group consisting of
(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]heptane-5-carboxylic acid (4-ethoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid (4-ethoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
2-methyl-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-ethoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7 morpholin-4-yl-benzothiazol-2-yl)-amide,
4-benzyl-4-hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
3-aza-spiro[5.5]undecane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
2-aza-bicyclo[2.2.2]octane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
(R)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
(S)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
4-(methanesulfonylamino-methyl)-pipendine-1-carboxylic acid (4 methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
piperidine-1,4-dicarboxylic acid 4-amide 1-[(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide],
(1R)-1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
2-oxa-5-aza-bicyclo[2.2.2]octane-5-carboxylic acid (4-methoxy-7 morpholin-4-yl-benzothiazol-2-yl)-amide,
1,4-diaza-bicyclo[3.2.1]octane-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide and
(1S,4R)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid (4-methox -7-morpholin-4-yl-benzothiazol-2-yl)-amide.

### Claim 3 (depends on 1)

A process for preparing a compound of form IA as defined in claim 1 comprising
reacting a compound of formula
with phenyl chloroformate and then with a compound of formula
HNR11R21 (3A)
forming a compound of formula

### Claim 4 (depends on 1)

A pharmaceutical composition comprising compound of formula IA according to claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically inert carrier.

### Claim 5 (depends on 1)

A method of neuroprotection and treating Alzheimer's disease, depressive disorders, drug addiction, Parkinson's disease and ADHD comprising administering a therapeutically effective amount of a compound of formula IA, or a pharmaceutically acceptable salt thereof, according to claim 1 to a person in need of such treatment.
